Browse

Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet.

The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.

The U.S. Food and Drug Administration issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), marking the first therapy for patients aged eight years and older with glycogen…